Edition:
United Kingdom

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

4.53EUR
8:11am GMT
Change (% chg)

€0.01 (+0.27%)
Prev Close
€4.52
Open
€4.52
Day's High
€4.54
Day's Low
€4.50
Volume
5,197
Avg. Vol
101,065
52-wk High
€10.95
52-wk Low
€4.36

Latest Key Developments (Source: Significant Developments)

Nicox Reports Cash And Cash Equivalents Of 25.7 Million Euros at Sept 30
Wednesday, 17 Oct 2018 

Oct 17 (Reuters) - NICOX SA ::REG-NICOX THIRD QUARTER 2018 BUSINESS UPDATE AND FINANCIAL HIGHLIGHTS.NCX 470 PHASE 2 CLINICAL STUDY INITIATED IN Q3 2018.NET REVENUE IN Q3 FROM VYZULTA SALES INCREASED BY 66% COMPARED TO Q2 2018.AS OF SEPTEMBER 30, 2018, CO HAD CASH AND CASH EQUIVALENTS OF €25.7 MILLION AS COMPARED WITH €32.7 MILLION AT JUNE 30.NET REVENUE FOR THE THIRD QUARTER OF 2018 WAS $0.438 MILLION.  Full Article

Nicox And Fera Pharmaceuticals Amend Their Agreement For Naproxcinod
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - NICOX SA ::REG-NICOX AND FERA PHARMACEUTICALS TO FOCUS ON A RARE DISEASE INDICATION FOR NAPROXCINOD.POTENTIAL SALES-BASED MILESTONE INCREASED TO $40 MILLION IF ANNUAL SALES REACH $1 BILLION.  Full Article

Nicox End-June Net Loss Is At 7.6 Million Euros
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - NICOX SA ::NCX 470 PHASE 2 CLINICAL STUDY INITIATED IN Q3 2018.AND CONTINUE DELIVERING ON ALL OBJECTIVES IN LINE WITH OUR GROWTH STRATEGY.NICOX EXPECTS TO REPORT TOP-LINE DATA FROM THIS PHASE 2 STUDY IN SECOND HALF OF 2019..PRECLINICAL AND FORMULATION DEVELOPMENT OF NCX 4251 IS CONTINUING ON TRACK FOR Q1 2019 IND SUBMISSION TO U.S FDA TO ENABLE A PHASE 2 STUDY.WE EXPECT TO SHIP COMMERCIAL PRODUCT AND TRADE SAMPLES FOR ZERVIATE 0.24% TO OUR PARTNER EYEVANCE BY Q1 2019.EYEVANCE TO LAUNCH ZERVIATETM IN UNITED STATES IN TIME FOR 2019 SPRING ALLERGY SEASON.NET REVENUE(1) FOR FIRST HALF OF 2018 WAS EUR 0.3 MILLION.OPERATING EXPENSES FOR FIRST HALF OF 2018 WERE EUR 10.0 MILLION FOR FIRST SIX MONTHS OF 2018 COMPARED TO EUR 10.2 MILLION FOR FIRST SIX MONTHS OF 2017.A NET LOSS OF EUR 7.6 MILLION FOR SIX MONTHS ENDED JUNE 30, 2018.AS OF JUNE 30, 2018 CASH AND CASH EQUIVALENTS OF EUR 32.7 MILLION AS COMPARED WITH EUR 36.3 MILLION AT MARCH 31, 2018 AND EUR 41.4 MILLION AT DECEMBER 31, 2017.  Full Article

Nicox Initiates Phase 2 Study Of NCX 470 In Open-Angle Glaucoma And Ocular
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - NICOX SA ::NICOX INITIATES PHASE 2 STUDY OF NCX 470 IN OPEN-ANGLE GLAUCOMA AND OCULAR.STUDY TO RANDOMIZE 420 PATIENTS IN CLINICAL SITES ACROSS U.S..TOP-LINE RESULTS EXPECTED H2 2019.TARGETS $5 BILLION WORLDWIDE GLAUCOMA MARKET.INITIATION OF A PHASE 2 CLINICAL STUDY EVALUATING NCX 470.  Full Article

Nicox Plans Start Of Phase 2 Clinical Study For NCX 470 In Q3 2018
Tuesday, 17 Jul 2018 

July 17 (Reuters) - NICOX SA ::NICOX Q2 2018 BUSINESS UPDATE AND FINANCIAL HIGHLIGHTS.Q3 2018: PLANNED START OF PHASE 2 CLINICAL STUDY FOR NCX 470 FOR THE REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION.FALL 2018: EXPECTED COMMERCIAL LAUNCH OF ZERVIATETM (CETIRIZINE OPHTHALMIC SOLUTION), 0.24% IN THE UNITED STATES BY PARTNER EYEVANCE PHARMACEUTICALS, LLC..Q1 2019: PLANNED U.S. INVESTIGATIONAL NEW DRUG SUBMISSION TO THE U.S. FDA FOR NCX 4251.AS OF JUNE 30, 2018, THE NICOX GROUP HAD CASH AND CASH EQUIVALENTS OF €32.6 MILLION VERSUS €36.3 MILLION AT MARCH 31, 2018.VYZULTA SALES GREW SUBSTANTIALLY IN THE Q2.  Full Article

Sellas Life Sciences Announces Appointment Of Gene Mack As Chief Financial Officer & Treasurer
Friday, 20 Apr 2018 

April 20 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES APPOINTMENT OF GENE MACK AS CHIEF FINANCIAL OFFICER & TREASURER.SELLAS LIFE SCIENCES GROUP INC - INTERIM CHIEF FINANCIAL OFFICER ALEKSEY KRYLOV WILL REMAIN WITH SELLAS UNTIL JULY 15.SELLAS LIFE SCIENCES GROUP INC - MACK MOST RECENTLY SERVED AS A CONSULTING CFO, MOST RECENTLY WITH NICOX, SA.  Full Article

Nicox Updates on Drug Development And Outlines 2018 Activities
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - NICOX SA ::RESOURCES IN 2018 WILL BE FOCUSED ON ADVANCING NICOX'S PIPELINE CANDIDATES NCX 470 AND NCX 4251 TOWARDS MID-STAGE CLINICAL DEVELOPMENT.ESTIMATES THAT THE U.S. PATENTS COVERING VYZULTA COULD BE EXTENDED FROM 2025 TO 2030..EXPECTS TO BEGIN RECEIVING ROYALTY REVENUE IN 2018, ALONG WITH POTENTIAL SALES AND DEVELOPMENT MILESTONES PAYMENTS‍​.NCX 470 TARGETING IND SUBMISSION FOR PHASE 2 IN 2018.NCX 4251 TARGETING IND SUBMISSION FOR PHASE 2 IN 2018.  Full Article

Bausch + Lomb and Nicox announces FDA approval of Vyzulta
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Valeant Pharmaceuticals International Inc :Bausch + Lomb and Nicox announce FDA approval of Vyzulta™ (latanoprostene Bunod Ophthalmic Solution), 0.024%.Valeant - ‍co's wholly owned subsidiary, Bausch + Lomb and Nicox S.A announced FDA approved NDA for Vyzulta​.  Full Article

Nicox says ‍cash balance was 47.1 million euros as of Sept. 30
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - NICOX SA ::‍CASH BALANCE OF EUR 47.1 MILLION AS OF SEPTEMBER 30, 2017​.Q3 NO REVENUE ‍​ VERSUS NO REVENUE YEAR AGO.  Full Article

Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Nicox SA :Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma​.Would make additional payments for any incremental development activities for each implant formulation product candidate.Expected payments from Nicox associated with agreement are not considered material to Nicox's financial statements at this time​.Says ‍pSivida will be responsible for initial development activities of ocular insert formulations, for which it will receive undisclosed sums​.  Full Article

Healthcare group Nicox postpones NASDAQ listing due to market volatility

PARIS, Oct 30 French healthcare and ophthalmology company Nicox said it had decided to postpone plans to list shares on the U.S. NASDAQ stock market, in the latest example of a company dropping stock market flotation plans due to market volatility.